Neoplasms
9 competing products in clinical development for Neoplasms.
Pipeline by Phase
Phase 16
Phase 1/22
Phase 21
All Products (9)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| enzastaurin | Eli Lilly | Phase 2 | Completed | 52 |
| LY3295668 | Eli Lilly | Phase 1/2 | Completed | 41 |
| Galunisertib + Gemcitabine + Placebo | Eli Lilly | Phase 1/2 | Completed | 41 |
| IMC-3C5 | Eli Lilly | Phase 1 | Completed | 33 |
| AB0024 | Gilead Sciences | Phase 1 | Completed | 32 |
| TTI-237 | Pfizer | Phase 1 | Terminated | 32 |
| 852A | Pfizer | Phase 1 | Completed | 32 |
| VIP152 (BAY 1251152) + VIP152 (BAY 1251152) 30 mg + Keytruda + VIP152 (BAY 1251152) 15 mg | Vincerx Pharma | Phase 1 | Completed | 25 |
| VIP236 (Q3W) + VIP236 (Q2W) | Vincerx Pharma | Phase 1 | Completed | 25 |